Viatris Inc. (NASDAQ: VTRS) has launched its alpha-adrenergic blocker Ryzumvi (phentolamine) in the US market, targeting the reversal of pharmacologically-induced pupil dilation caused by adrenergic agonists or parasympatholytic agents. The ophthalmic solution, which received regulatory approval last year, demonstrated in clinical trials that it could reverse eye dilation within 90 minutes for 49% to 58% of participants.
The procedure of inducing pupil dilation is commonly used by ophthalmologists to identify eye health issues, but the effect can persist for up to 24 hours, which can deter patients from undergoing the examination. Viatris’s Ryzumvi offers a potential solution to this issue, providing a faster return to normal pupil size and increasing the comfort and convenience for patients.
According to the company’s press release, approximately 100 million pupil dilations are performed annually in the United States, indicating a significant market potential for Ryzumvi as a treatment option for the rapid reversal of this effect.- Flcube.com
